<DOC>
	<DOCNO>NCT01692184</DOCNO>
	<brief_summary>This 2-part study . The first part evaluate safety , pharmacokinetics ( PK ) pharmacodynamics AVL-292 follow multiple oral dos ; second part evaluate effect food pharmacokinetics single oral dose AVL-292 .</brief_summary>
	<brief_title>Safety Pharmacokinetics AVL-292 Following Multiple Doses Effect Food Single-dose Pharmacokinetics AVL-292</brief_title>
	<detailed_description>Part 2 open-label , randomize , 2-period , 2-way crossover study evaluate effect standard high-fat breakfast pharmacokinetics AVL-292 . Ten subject enrol receive 2 single dos 200 mg AVL-292 , one food ( i.e. , feed ) without ( i.e. , fast ) , randomize sequence .</detailed_description>
	<criteria>Healthy male female subject ethnic origin age 18 65 body mass index 18 33 Recent history ( i.e. , within 3 year ) clinically significant neurological , gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , endocrine , hematological , dermatological , psychological , ophthalmological , allergic major disorder ; Use prescribe systemic topical medication within 30 day first dose ; Use nonprescribed systemic topical medication ( include vitamin/mineral supplement herbal medicine , e.g. , St. John 's Wort ) within 7 day first dose administration ; Exposure investigational drug ( new chemical entity ) within 30 day prior first dose administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>AVL-292</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacology , Clinical</keyword>
</DOC>